Cizzle Biotechnology sets date for Annual General Meeting

CIZ

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, announces that the Company’s notice of Annual General Meeting has been posted to shareholders and will shortly be available for viewing on the Company’s website at https://cizzlebiotechnology.com.

The Annual General Meeting will be held at 11:00 a.m. on Tuesday 16 June 2026 at the offices of Shakespeare Martineau LLP, C/O Ampa Holdings LLP, Level 19, The Shard, 32 London Bridge Street, London, United Kingdom, SE1 9SG.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Cizzle Bio advances lung cancer blood test towards clinical use

Cizzle Bio is moving its CIZ1B lung cancer blood test into commercial use in the US, with recent clinical research supporting its potential role as an additional tool alongside imaging and other established diagnostic methods.

Cizzle Biotechnology moves CIZ1B lung cancer test into commercialisation

Cizzle Biotechnology has moved its CIZ1B biomarker blood test into commercialisation after securing US clinical accreditation, with the company now focused on expanding access across North America and progressing opportunities in the UK and other international markets.

Cizzle Bio pushes blood test into lung cancer screening

Cizzle Bio is developing a blood test designed to add biomarker information to existing lung cancer screening.

Cizzle Bio expands the clinical pathway for CIZ1B Lung Cancer testing

Cizzle Bio has established a provider ordering and onboarding pathway for its CIZ1B lung cancer blood test in Dallas-Fort Worth and San Antonio, creating a structured route for clinical adoption.

Cizzle Biotechnology begins US commercial launch of lung cancer blood test

Cizzle Biotechnology has started the US commercial rollout of its CIZ1B lung cancer blood test through an initial launch in Texas.

Cizzle Bio signs second US laboratory agreement for lung cancer blood test

Cizzle Bio has partnered with BioBridge Global to validate and offer the CIZ1B Biomarker Blood Test through a CLIA-certified laboratory serving healthcare providers across South Texas.

Search